These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 1303133)

  • 1. Patients' perceptions on participation in a cancer chemoprevention trial.
    Tangrea JA; Adrianza ME; Helsel WE
    Cancer Epidemiol Biomarkers Prev; 1992; 1(4):325-30. PubMed ID: 1303133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. The Isotretinoin-Basal Cell Carcinomas Study Group.
    Tangrea JA; Adrianza E; Helsel WE; Taylor PR; Hartman AM; Peck GL; Edwards BK
    Cancer Epidemiol Biomarkers Prev; 1993; 2(4):375-80. PubMed ID: 8348061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.
    Levine N; Moon TE; Cartmel B; Bangert JL; Rodney S; Dong Q; Peng YM; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):957-61. PubMed ID: 9367070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
    Khuri FR; Kim ES; Lee JJ; Winn RJ; Benner SE; Lippman SM; Fu KK; Cooper JS; Vokes EE; Chamberlain RM; Williams B; Pajak TF; Goepfert H; Hong WK
    Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):823-9. PubMed ID: 11489748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin.
    Fine JD; Johnson LB; Weiner M; Stein A; Suchindran C
    J Am Acad Dermatol; 2004 Apr; 50(4):563-71. PubMed ID: 15034505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial.
    Pandeya N; Purdie DM; Green A; Williams G
    Am J Epidemiol; 2005 Apr; 161(8):748-54. PubMed ID: 15800267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
    J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of head and neck cancer with retinoids: a negative result.
    Perry CF; Stevens M; Rabie I; Yarker ME; Cochrane J; Perry E; Traficante R; Coman W
    Arch Otolaryngol Head Neck Surg; 2005 Mar; 131(3):198-203. PubMed ID: 15781758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
    Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
    J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients' perceptions on participation in a cancer chemoprevention trial.
    Tangrea JA; Adrianza ME; Helsel WE
    Cancer Epidemiol Biomarkers Prev; 1992; 1(3):325-30. PubMed ID: 11656233
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial.
    Sample DA; Sinicrope PS; Wargovich MJ; Sinicrope FA
    Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):281-5. PubMed ID: 11895878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.
    Moon TE; Levine N; Cartmel B; Bangert JL; Rodney S; Dong Q; Peng YM; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):949-56. PubMed ID: 9367069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isotretinoin-basal cell carcinoma prevention trial. Design, recruitment results, and baseline characteristics of the trial participants. The ISO-BCC Study Group.
    Tangrea J; Edwards B; Hartman A; Taylor P; Peck G; Salasche S; Menon P; Winton G; Mellette R; Guill M
    Control Clin Trials; 1990 Dec; 11(6):433-50. PubMed ID: 1963135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study.
    Cartmel B; Moon TE; Levine N; Rodney S; Alberts D
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):999-1002. PubMed ID: 11008922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer prevention in community clinics: will low-income Latina patients participate in clinical trials?
    Mandelblatt J; Kaufman E; Sheppard VB; Pomeroy J; Kavanaugh J; Canar J; Pallandre L; Cullen J; Huerta E
    Prev Med; 2005 Jun; 40(6):611-8. PubMed ID: 15850856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isotretinoin does not prevent basal cell carcinoma.
    Robinson JK; Salasche SJ
    Arch Dermatol; 1992 Jul; 128(7):975-6. PubMed ID: 1626967
    [No Abstract]   [Full Text] [Related]  

  • 17. Patients highly value routine follow-up of skin cancer and cutaneous melanoma.
    Themstrup L; Jemec GE; Lock-Andersen J
    Dan Med J; 2013 Oct; 60(10):A4713. PubMed ID: 24083527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral isotretinoin in the treatment and prevention of cutaneous squamous cell carcinoma.
    Jones E; Korzenko A; Kriegel D
    J Drugs Dermatol; 2004; 3(5):498-502. PubMed ID: 15552602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What motivates men age > or =50 years to participate in a screening program for melanoma?
    Janda M; Youl PH; Lowe JB; Baade PD; Elwood M; Ring IT; Aitken JF
    Cancer; 2006 Aug; 107(4):815-23. PubMed ID: 16832794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.